1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

 
• By Jessica Merrill

Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.

women's handshake
Organon partnered with ObsEva in women's health • Source: Alamy

Organon is making good on its promise to investors that it will build out its women's health portfolio. The company announced its first licensing deal on 27 July, in its second month after spinning out from Merck & Co. Organon bought worldwide licensing rights to ebopiprant for acute preterm labor in a deal with Swiss women's health specialist ObsEva SA.

Ebopiprant is a potential first-in-class selective prostaglandin F2α (PGF2α) receptor antagonist that could treat preterm labor by reducing inflammation and...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Immunological

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.

AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologics In COPD

 
• By Alexandra Shimmings

AstraZeneca’s IL-5 blocker has again missed in COPD, adding to a number of disappointments for biologics in this disease. Complex biology and overlapping inflammatory pathways seem to be at the heart of the problem.

EADV: Sanofi Smiles Again As Brivekimig Blooms In HS Study

 
• By Kevin Grogan

The dual TNFα/OX40L drug comfortably beat placebo in reducing symptoms of hidradenitis suppurativa but no news on Phase III plans yet.

Sobi Gets Ready To Take On Krystexxa In Uncontrolled Gout

 
• By Jessica Merrill

The company believes its novel treatment NASP could drive use in a category where medication is underutilized.

More from Therapy Areas

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.